KIT exon 11 mutation in GIST: imatinib 400 mg/day is standard 1L (B2222, Demetri NEJM 200...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-KIT-EXON11-GIST |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Erkrankungen | DIS-GIST |
| Quellen | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-KIT |
|---|---|
| Variante | exon 11 Löschung/Einfügung (Domäne Juxtammbrane — ~50% GIST) |
| Erkrankung | DIS-GIST |
| ESCAT-Stufe | IA |
| Empfohlene Kombinationen | imatinib 400 mg/day (1L advanced/metastatic), imatinib 400 mg/day adjuvant 3 yr (high-risk resected: ≥3 cm + mitoses ≥5/50 HPF, or rupture, or non-gastric primary), imatinib adjuvant 6 yr (extended for highest-risk per PERSIST-5 / SSG-XXII) |
| Zusammenfassung der Beweise | KIT exon 11 mutation in GIST: imatinib 400 mg/day is standard 1L (B2222, Demetri NEJM 2002 — ORR 67%; EORTC-62005 / S0033 confirmed long-term benefit). Exon 11 mutants have the longest PFS and OS on imatinib of any GIST genotype. Adjuvant imatinib 3 yr post- resection improves RFS in high-risk disease (SSG-XVIII / ACOSOG-Z9001). |
Anmerkungen
ESCAT IA. OncoKB Level 1. Source-gap: SRC-NCCN-SARCOMA / SRC-NCCN-GIST-2025 / SRC-B2222-DEMETRI / SRC-EORTC-62005 / SRC-SSG-XVIII not yet ingested — using SRC-NCCN-MELANOMA-2025 placeholder per DIS-GIST source gap. SRC-IRIS-OBRIEN-2003 cited as the imatinib pivotal CML/GIST-era reference. Resistance: secondary KIT exon 13/14 (ATP-binding) or 17/18 (activation loop) mutations emerge during therapy.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.